Babak Edraki

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Journal of Clinical Oncology · 2018 · 525 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Clinical Cancer Research · 2020 · 308 citations · Full text

Medicine, Oncology, Pharmacology +17

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

Siming Zhao, Stefania Bellone, Salvatore Lopez et al. · Proceedings of the National Academy of Sciences · 2016 · 232 citations · Full text

Medicine, Genetics, Oncology +17

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11